MDACC Study No:2011-0757 ( NCT No: NCT01295827)
Title:Phase I Study of Single Agent MK-3475 in Patients with Progressive
Locally Advanced or Metastatic Carcinomas, Melanoma and Non-Small Cell Lung Carcinoma
Principal Investigator:Wen-Jen Hwu
Treatment Agent:MK-3475
Study Status:Closed
Study Description:There are 5 parts to this clinical research study. MD Anderson will be
taking part in Parts B, D, and F. This consent form will cover Parts B, D, and

The goal of Part B is to further test the highest tolerable dose of MK-3475
(pembrolizumab) that was found in Part A when given to patients with melanoma.
The safety of this drug will also be studied.

The goal of Part D is to study 2 dose levels of pembrolizumab when given to
patients with melanoma.

The goal of Part F is to study 2 dose levels of pembrolizumab when given to
patients with lung cancer.

Pembrolizumab is a drug that includes a protein naturally created by living
cells. It is designed to help the body's natural defense system react against
tumors by blocking proteins that cancers cells create to "turn off" the body's
immune (defense) system.
Hide details for General InformationGeneral Information

Disease Group:Lung; Melanoma
Phase of Study:Phase I
Treatment Agents:MK-3475
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Merck
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wen-Jen Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults